AstraZeneca Pharmaceuticals LP v. Blue Cross Blue Shield of Massachusetts
177 L. Ed. 2d 1150, 131 S. Ct. 60, 561 U.S. 1056, 2010 U.S. LEXIS 5762
Supreme Court of the United States·Decided September 28, 2010·No. No. 09-1069 (R46-032)·Published·Cited by 3 cases
Opinion
The petition for writ of certiorari to the United States Court of Appeals for the First Circuit in the above-entitled case was dismissed today pursuant to Rule 46 of the Rules of this Court.
Same case below, 582 F.3d 156.
Free access — add to your briefcase to read the full text and ask questions with AI
AstraZeneca Pharmaceuticals LP v. Blue Cross Blue Shield of Massachusetts, 177 L. Ed. 2d 1150, 131 S. Ct. 60, 561 U.S. 1056, 2010 U.S. LEXIS 5762 (U.S. 2010).
177 L. Ed. 2d 1150 (AstraZeneca Pharmaceuticals LP v. Blue Cross Blue Shield of Massachusetts) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.
Related
Federated Ins. Co. v. Summit Pharmacy (WC Fee Rev. Hearing Office)
Commonwealth Court of Pennsylvania, 2024
Commonwealth v. Ortho-McNeil-Janssen Pharmaceuticals, Inc.
52 A.3d 498 (Commonwealth Court of Pennsylvania, 2012)
Com. v. TAP PHARMACEUTICAL PRODUCTS, INC.
36 A.3d 1112 (Commonwealth Court of Pennsylvania, 2011)